As on Thursday, Relay Therapeutics Inc (NASDAQ: RLAY) got off with the flyer as it spiked 13.39% to $4.32, before settling in for the price of $3.81 at the close. Taking a more long-term approach, RLAY posted a 52-week range of $3.77-$11.16.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was 399.77%. Meanwhile, its Annual Earning per share during the time was -38.74%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 9.80%. This publicly-traded company’s shares outstanding now amounts to $166.89 million, simultaneously with a float of $123.45 million. The organization now has a market capitalization sitting at $723.10 million. At the time of writing, stock’s 50-day Moving Average stood at $4.80, while the 200-day Moving Average is $6.47.
Relay Therapeutics Inc (RLAY) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Relay Therapeutics Inc’s current insider ownership accounts for 26.25%, in contrast to 73.18% institutional ownership. According to the most recent insider trade that took place on Jan 03 ’25, this organization’s insider sold 32,177 shares at the rate of 4.30, making the entire transaction reach 138,361 in total value, affecting insider ownership by 325,330. Preceding that transaction, on Jan 02 ’25, Company’s insider sold 32,156 for 4.15, making the whole transaction’s value amount to 133,447. This particular insider is now the holder of 357,507 in total.
Relay Therapeutics Inc (RLAY) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.61 per share during the current fiscal year.
Relay Therapeutics Inc’s EPS increase for this current 12-month fiscal period is 9.80% and is forecasted to reach -2.64 in the upcoming year.
Relay Therapeutics Inc (NASDAQ: RLAY) Trading Performance Indicators
Let’s observe the current performance indicators for Relay Therapeutics Inc (RLAY). It’s Quick Ratio in the last reported quarter now stands at 18.42. The Stock has managed to achieve an average true range (ATR) of 0.50. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 72.24.
In the same vein, RLAY’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.61, a figure that is expected to reach -0.57 in the next quarter, and analysts are predicting that it will be -2.64 at the market close of one year from today.
Technical Analysis of Relay Therapeutics Inc (RLAY)
Through scrutinizing the latest numbers posted by the [Relay Therapeutics Inc, RLAY], it can be observed that its last 5-days Average volume of 5.4 million was better the volume of 3.5 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 17.43% While, its Average True Range was 0.58.
Raw Stochastic average of Relay Therapeutics Inc (RLAY) in the period of the previous 100 days is set at 11.36%, which indicates a major fall in contrast to 32.93% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 107.93% that was higher than 97.47% volatility it exhibited in the past 100-days period.
